NCT06900725View on ClinicalTrials.gov

Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
ElderlyAtrial Fibrillation (AF)Ischemic Stroke
Interventions
DRUG

edoxaban

edoxaban 15 mg daily will be administered to the patients as secondary stroke prevention.

DRUG

Edoxaban 30 mg

edoxaban 30 mg daily will be administered to the patients as secondary stroke prevention.

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

National Taiwan University Hospital, Yun-Lin Branch

OTHER

collaborator

National Taiwan University Hospital Hsin-Chu Branch

OTHER

lead

National Taiwan University Hospital

OTHER

NCT06900725 - Low Dose Edoxaban in Elderly Patients With AF and a History of Stroke | Biotech Hunter | Biotech Hunter